Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406281 | 1.00 | HDAC1 (0.62) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2404014 | 0.90 | HDAC1 (0.64) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2404017 | 0.90 | HDAC1 (0.64) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2402847 | 0.83 | HDAC6 (0.66) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2402850 | 0.83 | HDAC6 (0.66) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2403216 | 0.83 | HDAC6 (0.76) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2403223 | 0.83 | HDAC6 (0.76) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2403825 | 0.82 | HDAC6 (0.68) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2403827 | 0.82 | HDAC6 (0.68) | HDAC1HDAC3HDAC8HDAC6HDAC2 | |
| SCHEMBL2403348 | 0.81 | HDAC1 (0.64) | HDAC1HDAC3HDAC8HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | claimed |
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212943-A1 | NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885HDAC3 10/4885HDAC8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.